Twist Bioscience (TWST) Stock May Look Rich As Sales Face A High Bar

Twist Bioscience has seen its share price surge over the past few years, which puts fresh focus on what buyers today are really paying for in terms of sales. With the stock now well above where it traded several years ago, the key issue is how that market enthusiasm lines up with the revenue it currently generates.

• Over the past 3 years, Twist Bioscience has delivered a gain of 364.8%, which puts considerable pressure on its sales base to support the current share price.
• The business model relies heavily on scaling synthetic DNA production and related services. This can influence both revenue growth potential and how efficiently those sales convert into cash over time.
• Your read on Twist Bioscience is one view; the desks covering it have another. See what analysts think Twist Bioscience's shares could be worth.

The stock's next move may depend on whether Twist Bioscience's present valuation is well grounded in the level and trajectory of its sales.

If you are questioning whether Twist Bioscience's recent share price gain is well aligned with its sales, it can help to compare that same sales lens across 32 high quality undervalued stocks.

Does Twist Bioscience Look Pricey on Sales?

P/S makes more sense for Twist Bioscience because investors are paying far more attention to the revenue stream than to current earnings. The stock trades on a P/S of 15.2x, compared with a Biotechs industry average of 9.8x and a peer group average of 14.1x. That points to buyers paying a richer price for each dollar of Twist Bioscience sales than for many comparable lab and genomics businesses.

The Fair Ratio model, which adjusts the P/S benchmark for Twist Bioscience’s own growth expectations, margins, size and risk profile, sits below the current 15.2x level. That gap implies the shares screen overvalued on this measure. Anyone considering the stock needs to judge whether the company’s revenue quality and long term opportunity justify paying a premium to both sector norms and its tailored benchmark. Explore the numbers behind Twist Bioscience's P/S valuation.

The Twist Bioscience Narrative: What Would Justify Today's Price?

Narratives for Twist Bioscience pick up where the valuation puzzle leaves off and explain which combinations of future growth, profitability and earnings power would need to occur for the stock to appear meaningfully cheaper or more expensive than it does today on Simply Wall St's Community page. Each narrative links its implied value to a specific view on how Twist Bioscience's revenue trajectory, margins and risk profile might evolve, giving you a reference point to revisit as fresh information becomes available.

One of the top narratives on Twist Bioscience: 34% undervalued

This narrative is the analyst consensus Narrative on Simply Wall St, which compiles analysts' consensus price target and revenue and earnings forecasts, not one person's view.

"Orders tied to AI-enabled drug discovery are expected to grow at triple digit rates in fiscal 2026 and again in 2027 off at least US$25 million…"

Discover why this Narrative puts Twist Bioscience at 34% undervalued.

For Twist Bioscience, the price is only one part of the story

Share price and sales only tell you where Twist Bioscience stands today. Analyst modelling sketches out where the business could be in a few years and how that lines up with the current tag. Explore where analysts expect Twist Bioscience to be in a few years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com